NewsRx

Search our medical news database

Conference Coverage (Lancet Conference)

Immunotherapy Agent SRL 172 Shows Promise Against TB

Published in TB and Outbreaks Week, October 2nd, 1995

Animal and human trials from Great Britain suggest that the candidate immunotherapy agent SRL 172 is a useful adjunct to standard chemotherapy in the treatment of tuberculosis.

As a result of these trials large-scale efficacy studies are underway in the Republic of South Africa and the United Kingdom.

Researcher J.L. Stanford and colleagues presented the results of preliminary animal and human trials of SRL 172 at The Lancet Conference 1995, "The Challenge of Tuberculosis," held in Washington D.C., September 14 and 15, 1995.

SRL 172 is a suspension of heat-killed Mycobacterium vaccae, NCTC 11659, 0.1 ml of which contains 1...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook